Mydecine Innovations Group Inc is a CA-based company operating in Pharmaceuticals industry. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2014-08-18. Mydecine Innovations Group Inc. is a Canada-based biotechnology company. The firm is engaged in developing the next generation of medications and therapies to address mental health disorders, such as nicotine addiction and post traumatic stress disorder (PTSD). The firm conducts research and development on novel second generation compounds in Canada with a focus on developing and commercializing psychedelic-inspired regulated medicines. The firm has two lead 3,4-Methylenedioxymethamphetamine (MDMA) candidates. The firm is channeling its MYCO-005, MYCO-006, and MYCO-007 families of patent-pending second-generation MDMA and Psilocybin analogs through Applied Pharmaceutical Innovation (API). The company uses advanced artificial intelligence (AI) and machine learning to design and screen drugs of interest. Its subsidiaries include Mydecine Group (1220611 BC Ltd) and NeuroPharm Inc.
Leveraging in-depth analyst evaluations, we have synthesized key insights from expert assessments to present a positive outlook for MYCOD. Analysts highlight solid fundamentals and favorable market sentiment, suggesting upside potential in the near term. Based on this thorough expert analysis, we maintain an optimistic view of this stock. Our conclusion: MYCOD is a Buy candidate.
MYCOD stock price ended at $0.1 on 木曜日, after dropping 58.33%
On the latest trading day Nov 06, 2025, the stock price of MYCOD fell by 58.33%, dropping from $0.10 to $0.10. During the session, the stock saw a volatility of 0.00%, with prices oscillating between a daily low of $0.10 and a high of $0.10. On the latest trading day, the trading volume for MYCOD rose by 497 shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 605 shares were traded, with a market value of approximately $123.5K.